Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease

B oston, MA (June 3, 2024) – Glyscend Therapeutics… today announced the initiation of a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity. GLY-200 previously demonstrated clinically meaningful reductions in fasting and postprandial glucose, fasting lipids, body weight, food intake, and appetite versus placebo in a completed two-week study in patients with type 2 diabetes and was also shown to be well-tolerated with no treatment-related safety signals. This ongoing Phase 2 trial is designed to evaluate the efficacy, safety, and tolerability of GLY-200 in a non-diabetic obese population. LEARN MORE

The release as fetched from its publisher. glyscend.com ↗